Have regulators historically allowed enough time for Phase 3 trials to show that a vaccine does not cause congenital defects? Are they making an exception for Covid vaccines?
Because the Pfizer/Biontech vaccine for coronavirus is now available for all over-16s in Israel (see https://www.ft.com/content/0cdc8563-1e6d-4089-bedb-b0f675c0d683 ), but I wonder whether it would not have been better to wait a few months to give Phase 3 trials a chance to yield data on congenital defects after some participants give birth. (Phase 3 trials started on July 27 according to https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine ). What do we know about the Pfizer/Biontech vaccine which would make researchers confident that it doesn't cause congenital defects? What data do we have to show it does or doesn't? When did/would we get this data? Did the Israeli regulator decide to take a risk in the absence of data?
I am also interested in these questions applied to the Oxford/AstraZenica vaccine, Moderna vaccine, and other regulators/vaccine approval processes for coronavirus vaccines.